✦ LIBER ✦

Future of Ophthalmic Anti-infective Therapy and the Role of Moxifloxacin Ophthalmic Solution 0.5% (VIGAMOX®)

✍ Scribed by Barry A. Schlech; Joseph Blondeau

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Overview of the Potency of Moxifloxacin

✍ Barry A. Schlech; Eduardo Alfonso 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Clinical Safety of Moxifloxacin Ophthalm

✍ Lewis H. Silver; Adrienne M. Woodside; Dawnelle B. Montgomery 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Aqueous penetration of moxifloxacin 0.5%

✍ Junko Yoshida; Alisa Kim; Kimberly A. Pratzer; Walter J. Stark 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Efficacy and Safety of Besifloxacin Opht

✍ Marguerite B. McDonald; Eugene E. Protzko; Lynne S. Brunner; Timothy W. Morris; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 923 KB

In Vitro and In Vivo Potency of Moxiflox

✍ David W. Stroman; Joseph J. Dajcs; Gale A. Cupp; Barry A. Schlech 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 377 KB

The effects of moxifloxacin ophthalmic s

✍ K. Keven Williams; Mitchell D. McCartney; Rebecca L. Rice; Martin B. Wax; Joseph 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB